A study led by investigators from Mass Eye and Ear found that patients prescribed semaglutide (as Ozempic or Wegovy) for diabetes or weight loss had a higher risk of having a potentially blinding eye condition called NAION (non-arteritic anterior ischemic optic neuropathy) than similar patients who had not been prescribed these drugs.
Medical Xpress – latest medical and health news stories
